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1 Attribute description
Biomarkers, type categorical (C) or numerical (C) and short description.
Biomarker Type Values range
age N <60, 60-65, 66-70, 71-75, 76-80, >80
sex C F, M
hyper C
Diagnosis of Hypertension Low-grade (<160/90 mm Hg; medications are not
used, or used irregularly), High-grade (>160/90 mm Hg; medications are used
regularly)
DM C Diagnosis of Diabetes mellitus type 2 yes, Impaired glucose tolerance, No
HbA1c N
Glycosilated Haemoglobin (%) - a marker of an average blood glucosein a
three-month period Please, split the range of values into tertiles or quartiles,
as appropriate
Fglu N Fasting glucose (mmol/L) - a marker of glucose metabolism
Chol N
Total cholesterol Please, split the range of values into tertiles or quartiles, as
appropriate
HDL N
HDL-cholesterol Please, split the range of values into tertiles or quartiles, as
appropriate
Statins C Statins use Yes, No
anticoag C
Therapy with oral anticoagulant drug (warfarin), therapy with antiaggregant
drug (aspirin), therapy with antiaggregant plant drug (ginkgo)
CVD C
Cardiovascular disease. No, myocardial infarction/angina/history of
revascularization, chronic myocardiopathy with atrial fibrillation, chronic
myocardiopathy without atrial fibrillation, stroke/transient ischaemic cerebral
event, carotid artery atherosclerosis confirmed by using image techniques,
peripheral vascular disease
BMI N Body mass index (a measure of the body weight) <20, 20-25, 26-29, >=30
w/h N Weist to hip ratio - M <1.0, >=1.0; F <0.8, >=0.8
skinf N
Triceps skinfold thickness Please, split the range of the values into tertiles,
separately for M and F
COPD C Chronic Obstructive Pulmonary Disease – Yes, No
Aller d C Allergic disease (rhinitis/asthma) - Yes, No
Dr aller C Allergy to drugs - Yes, No
Analg C Long-term use of analgesics/nonsteroidal antiinflammatory drugs - Yes, No
Neo C No, malignant disease in a stable phase, skin malignancy
Derm C Chronic skin disorders Chronic dermatitis, dermatomycosis, No
OSP C
Osteoporosis - an age-related disease affecting mostly women, characterized
with increased bone fragility and susceptibility for fracture.
Osteoporosis/osteopenia/no - of the radius bone; osteoporosis/osteopenia/no
- of the vertebrae; osteoporosis/osteopenia/no - of the hip
Psy C Anxyety/depression, Parkinson‘s disease, cognitive impairment, no
MMS N
Neuropsychologic test for screening on cognitive impairment ”Mini Mental
Score” <10 severe cognitive imapirment, 10 - 20 moderate, 21 - 24 mild, 25 -
30 normal cognition
CMV N
Cytomegalovirus infection (specific IgG antibodies, IU/ml). Please, split the
range of values into tertiles, or quartiles, if appropriate
EBV N
Epstein-Barr virus infection (specific IgG antibodies, IU/ml). Please, split the
range of values into tertiles, or quartiles, if appropriate
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Biomarker Type Values range
HPA N
Helicobacter pylori infection (specific IgA antibodies, IU/ml). Please, split
the range of values into tertiles, or quartiles, if appropriate
LE N
White blood cell (WBC) count (Leukocytes number × 109/L). Please, split
the range of values into tertiles, or quartiles, if appropriate
CRP N
C-reactive protein (mg/L). Please, split the range of values into tertiles, or
quartiles, if appropriate
GAMA N Hiper-gamma-globulinemia (g/L) - a marker of chronic inflammation
MO N
Monocytes % in WBC differential. Please, split the range of values into
tertiles, or quartiles, if appropriate
NEU N
Neutrophils % in WBC differential. Please, split the range of values into
tertiles, or quartiles, if appropriate
LY N
Lymphocytes % in WBC differential Please, split the range of values into
tertiles, or quartiles, if appropriate
E N
Red Blood Cell (RBC) count (Erythrocytes number × 1012/L) Please, split
the range of values into tertiles, or quartiles, if appropriate
HB N
Hemoglobin (g/L). Please, split the range of values into tertiles, or quartiles,
if appropriate
HTC N
Hematocrite (Erythrocyte volume blood fraction) Please, split the range of
values into tertiles, or quartiles, if appropriate
MCV N
RBC Mean Cell Volume (fL). Please, split the range of values into tertiles, or
quartiles, if appropriate
FE N
Serum iron (g/L). Please, split the range of values into tertiles, or quartiles, if
appropriate
ALB N
Serum albumin (g/L). Please, split the range of values into tertiles, or
quartiles, if appropriate
Clear N
Creatinine clearance - an indicator of chronic renal impairment (ml/s/1.73m2)
Please, split the range of values into tertiles, or quartiles, if appropriate
HOMCIS N
Homocystein (µmol/L)- sulphuric amino-acid Please, split the range of values
into tertiles, or quartiles, if appropriate
VITB12 N
Vitamin B12 (pmol/L) Please, split the range of values into tertiles, or
quartiles, if appropriate
FOLNA N
Folic acid (mM/L) Please, split the range of values into tertiles, or quartiles,
if appropriate
INS N
Serum fasting insulin (IU/ml) Please, split the range of values into tertiles, or
quartiles, if appropriate
CORTIS N
Serum cortisol in the morning (nmol/L) Please, split the range of values into
tertiles, or quartiles, if appropriate
PRL N
Prolactin in the morning (mIU/L) - the anterior pituitary gland hormone
Please, split the range of values into tertiles, or quartiles, if appropriate
TSH N
Thyroid-stimulating hormone (IU/ml) - the anterior pituitary gland hormone
Please, split the range of values into tertiles, or quartiles, if appropriate
FT3 N
Free triiodothyronine (pmol/L) - the thyroid gland hormone Please, split the
range of values into tertiles, or quartiles, if appropriate
FT4 N
Free thyroxine (pmol/L)- the thyroid gland hormone Please, split the range of
values into tertiles, or quartiles, if appropriate
RF N
Rheumatoid factor - the auto-antibody, increased in patients with rheumatoid
arthritis In cases where RF is tested positive, please, split the range of values
into tertiles, or quartiles, if appropriate
ANA N
Anti-nuclear antibody - the auto-antibody - a diagnostic marker in rheumatic
autoimmune diseases Please, split the range of values into tertiles, or
quartiles, if appropriate
IGE N
Immunoglobuline E - a class of antibody included in the allergic reactions
Please, split the range of values into tertiles, or quartiles, if appropriate
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2 Attribute risk description
Attribute Description References
age
The strongest risk factor for death. In general: the older the person, the
higher the risk of death; although, due to the remodelling theory of aging, the
mortality rates are the highest at the age of around 75, due to the chronic
disease burden; after the age of 80, the population mortality curve starts to
slowdown, reflecting the positive selection of oldest old individuals, who are
also characterized with better coping mechanisms
1-2
sex
For some pathophysiological aspects of ageing, such as diabetes and metabolic
syndrome, there is a presumption that men and women use different
pathways to attain ageing diseases and premature mortality (or longevity)
3-4 &
Presumption
hyper
Hypertension is the main risk factor for cardiovascular disease - the main
mortality cause in European countries. Thus, the higher grade hypertension -
the stronger association with mortality. On the other hand, persons with high
grade hypertension more regularly use anti-hypertensive drugs, which may, in
turn, elicit the protective effect
5-6 &
Presumption
& Intuition
DM
Diabetes mellitus,mostly based on the pre-existing obesity, is the main risk
factor for cardiovascular disease - the main mortality cause in European
countries. Thus, diabetics might have the highest mortality risk, in
comparison to non-diabetics and those having pre-diabetes (impaired glucose
tolerance). However, there might be an alleviating effect of drug treatment, in
diabetic patients. Another contradictory argument is the fact that impaired
glucose tolerance is a condition characterized with high insulin resistance and
insulin serum concentrations -both factors confirmed as to have the strong
impact on the development of many aging diseases. In addition, among those
subjects not having diabetes, there might be some individuals characterized
with frailty - another strong mortality risk factor.
7-9 &
Presumption
& Intuition
HbA1c
According to the above commentaries and the remodelling theory of aging,
both lowered and increased values of Hba1c - a measure of blood glucose
concentrations - may be detrimental for healthy aging and longevity. An
intriguing is also to note that, in diabetics, the HbA1c values are under the
influence of treatment
10-11 &
Presumption
& Intuition
FGlu Fasting Glucose – a marker of glucose metabolism
chol
High serum concentrations of total cholesterol is well established as the main
risk factor for cardiovascular disease and, as such, it can be also associated
with premature death. On the other hand, hypolipemic treatment with
statins is less efficient in elderly people, which may implicate weaker influence
of total cholesterol as CV risk factor, in this population group. Also, therapy
with statins, mostly used by diabetics, is known to modify the total
cholesterol levels.
12-13 &
Presumption
HDL
High serum HDL-cholesterol concentrations (certainly ¿1.0 mmol/L) is
thought to be protective against diabetes, cardiovascular disease and
Alzheimer‘s dementia, so also against premature death. A conflicting fact is
that recent evidence implicate not only low serum concentrations of
HDL-cholesterol, but also functionally defective HDL particles, as to be
detrimental for the development of age-related chronic diseases. In general,
low serum HDL-cholesterol concentrations - a cardiovascular risk factor - can
be expected in conditions associated with insulin resistance, including obesity,
especially abdominal obesity, diabetes, hypertension, CVD, chronic renal
impairment and frailty (muscle wasting).
14-15 &
Presumption
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Statins
Therapy with statins can modify the total cholesterol levels, so can be
protective for premature cardiovascular disease and death. Although, recent
studies indicate lower effectiveness of this therapy in elderly population. Also,
there are ambiguous results in respect to statins use and the development of
cognitive dysfunction/dementia -an emerging cause of death in modern
societies.
13, 16-17 &
Presumption
anticoag
Oral anticoagulant/antiaggregant drug treatment is a part of a secondary
prevention strategy of CVD and can be a marker of higher CV risk and
death. On the other hand, the effect of this therapy on CVD and average life
expectancy can be beneficial. Therapy with these medications can yet be
associated with potential adverse effects and serious complications. Further,
there might be a difference between the effectiveness of anticoagulant and
antiaggregant drugs.
18-20 & Pre-
sumption,
Intuition
CVD
Cardiovascular disease is the major cause of mortality. However, there may
be differences in respect to an influence of age, gender, co-morbidity, or a
specific CVD entity (for example, stroke vs peripheral vascular disease)
21 & Pre-
sumption,
Intuition
BMI
Evidence say that both, low values of BMI (<20) and high values (>=30),
may contribute to CV and overall mortality. Overweight (BMI 26-29) may
also have unfavourable effect. However, there are no clear relationships
between BMI and other CV risk factors, such as lipids, hypertension and
insulin resistance, as well as in respect to gender and age differences.
10,22-25 &
Presump-
tion,
Intuition
w/h
Increased weist cicumference and weist to hip ratio are well established
measures of insulin resistance and CV risk factors, either being associated
with obesity, or frailty. The strength of associations with the risk of mortality
is not well known.
25
skinf
Increased triceps skinfold thickness is validated as an anthropometric measure
of insulin resistance state (muscle wasting). Data on the strengh of
associations towards CVD and overall mortality are not yet conclusive.
26-27
COPD
COPD is a major cause of mortality and also a CV risk factor. There may be
a survival benefit for treatment with new inhalatory drugs, however,
conclusive data are currently lacking.
28
Aller d
Allergic diseases have in the background increased activity of the
antibody-mediated (humoral) immune response (represented with high serum
IgE concentrations). In this sense, these diseases may elicit protective effects
towards CVD and premature death, as CVD and some other aging diseases,
including dementia and cancer, use cell-mediated immunity during their
pathogenesis. Although strong evidence are lacking, recent advances in aging
process propose that the development of the main aging diseases is the result
of the unsuccessful modeling, which is associated with the bias of the immune
reaction into the cell-mediated and antibody-mediated immune response. In
this context, the bias towards humoral (antibody-mediated) immunity is
associated with the development of allergic diseases and hematoproliferative
disorders. These latter disorders, in turn, may be unfavourable for survival.
1,29-32 &
Presump-
tion,
Intuition
Dr aller
Drug allergy might be a marker of multimorbidity and, as such, of the
complex unfavourable pathogenetic background
33 & Pre-
sumption,
Intuition
Analg
Analgesics can alleviate inflammation - according to the theory - the main
driving cause of age-related diseases. So, this therapy might be beneficial for
survival, although it can be accompanied with the serious side effects, for
example decline of renal function. Alternatively, use of these medications can
be a marker of a subgroup of patients with locomotor disease in its active
phase - characterized with increased level of inflammation, which, in turn,
may be non beneficial for survival
18,19 & Pre-
sumption,
Intuition
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Neo
Patients in the stable phase of malignant disease, including those with skin
cancer, might be in an unfavourable position in respect to survival, because of
the immune system impairment. According to the recent theories of aging,
unsuccessful remodelling of the metabolic, the immune and the
neuro-endocrine systems is responsible for increased level of inflammation and
the development of the age-related chronic diseases.
29, 34 &
Presump-
tion,
Intuition
Derm
Chronic skin disorders can be a marker of the immune system dysfunction
and, as such, of an unfavourable survival pattern
35 & Pre-
sumption,
Intuition
OSP
Osteoporosis is an inflammation-mediated disease, so unfavourable for
survival. Overt osteoporosis may be more detrimental than the disease in its
early phase - osteopenia. Although, in an early phase of this disease, the level
of inflammation can be even at the higher level than when the disease turns
into its advanced stage. This is supported by the evidence implicating
osteopenia as a component of the frailty syndrome, characterized with
increased level of inflammation. Osteoporosis is a spot like disease, so the
larger the number of invloved sites, the greater the influence of the disease on
the survival
36-37 & Pre-
sumption,
Intuition
Psy
Anxyety-depresson and cognitive disorders are all known to activate the
hypothalamo-pituitary-adrenal (HPA) axis, which decreases an individual‘s
adaptation to infections and illnesses, mostly due to the immune system
impairment and increased secretion of inflammatory cytokines and other
mediators. So, these diseases are unfavourable for survival.
38-39 & Pre-
sumption,
Intuition
MMS
MMS < 25 is a measure of mild cognitive impairment (MCI) - an early phase
during the course of the development of dementia . Some known factors
responsible for progression of MCI to dementia include deficit of folic acid and
vitamin B12, the thyroid gland hypofunction and depression/anxyety.
Although not all persons with MCI get dementia, this condition is associated
with the immune system bias towards the cell-mediated immunity, which may
affect survival.
40 & Pre-
sumption,
Intuition
CMV
Latent infections reactivation is a feature of unsuccessful aging. High serum
specific IgG antibody concentrations can be used as a marker of CMV
infection reactivation. This condition is a driving force for cellular immunity
activation and exhaustion. High serum concentrations of specific IgG
antibodies have been accepted as the risk factor for frailty and premature
death.
41-42 &
Presumption
EBV
High serum specific IgG antibody concentrations can be considered as a
marker of the immune system impairment and bias towards B lymphocytes
(humoral immunity) domination. In this sense, this condition might be
beneficial for survival, by turning the immune reaction from the cellular
towards the domination of humoral immunity, avoiding the development of
the main aging diseases, including CVD, dementia and cancer. On the other
hand, EBV infection is a driving force for the development of lymphomas and
lymphoproliferative disorders, which might be unbeneficial for survival.
43 &
Presumption
HPA
Helicobacter pylori infection, a cause of chronic gastritis, is a wide-spread
condition in older population. Because of its association with increased
systemic inflammation and biased immune reaction in favour of cell-mediated
immunity, this infection might be unbeneficial for survival. Increased serum
concentrations of specific IgA antibodies (>11.1 IU/ml) is a diagnostic test
used to confirm this infection.
44-45 &
Presumption
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LE
Leukocyte count, a marker of inflammation, is frequently included in routine
clinical checkups. According to the recent studies, increased leukocyte count,
in apparently healthy elderly population, can be used as a prognostic factor of
all-cause and cardiovascular mortality. Aspirin and nonsteroidal
antiinflammatory drugs may lower their counts.
18, 46 &
Presumption
CRP
Low grade chronic inflammation, as indicated with slightly elevated serum
concentrations of CRP (even in the upper part of the reference range), has
been considered as the main pathogenetic driving force in the progression of
the main aging chronic diseases, including CVD, dementia, osteoporosis,
cancer, autoimmune and lymphoproliferative diseases. In addition, it may
also play a major role in the development of the frailty syndrome, which in
older persons is associated with increased vulnerability for disease and death.
Phenotipically, this syndrome is characterized with lean body mass,
osteopenia, anemia and low cholesterol level.
The etiology of chronic inflammation is considered to be multifactorial. One
of the best accepted cause is obesity. In this condition, low grade
inflammation is associated with insulin resistance and impaired glucose
tolerance, increasing, in obese people, their susceptibility for diabetes and
CVD. More generally, it is thought that age-related dysfunction in the
metabolic, the neuroendocrine and the immune system, is associated with
chronic low grade inflammation.
Increased serum CRP concentrations have been found to be associated with
increased risk of CV and all-cause mortality.
1,18,29,30,
47 &
Presumption
GAMA Hiper-gamma-globulinemia – a marker of chronic inflammation
MO
Mononuclear leukocytes are included in cell-mediated immunity during
pathogenesis of atherosclerotic CVD, dementia and cancer. Although
monocytes % in WBC differential is a weaker marker of cell-mediated
immunity than absolute monocytes number, it is more easily available in
clinical practice. Some age-related changes in WBC differential, including
slightly increased monocytes %, decreased lymphocytes % and increased
neutrophils %, have been found as to have predict ive power in CV and
all-risk mortality.
48-49 &
Presumption
NEU
Some age-related changes in WBC differential, including slightly increased
monocytes %, decreased lymphocytes % and increased neutrophils %, have
been found as to have predict ive power in CV and all-risk mortality.
48-49 &
Presumption
LY
Some age-related changes in WBC differential, including slightly increased
monocytes %, decreased lymphocytes % and increased neutrophils %, have
been found as to have predict ive power in CV and all-risk mortality.
48-49 &
Presumption
E
Erythrocytes (RBC) number is a routine laboratory test indicating blood
oxygen carrying capacity, or otherwise, used to diagnose anaemia. According
to the evidence, anemia, in older persons, as indicated by lower Hemoglobin
and Erythrocytes number, is associated with an increased mortality risk. On
the other hand, even slightly increased erythrocytes number, due to hypoxic
lung or heart diseases, can affect blood rheological properties and vascular
resistance, increasing the risk for unfavourable outcomes.
50-52 & Pre-
sumption,
Intuition
HB
Hemoglobin is a more sensitive marker of anemia than erythrocytes number.
Both, decreased HB values (indicating anaemia) and increased HB values
(corresponding with impaired blood rheology) might be unfavourable for
survival.
50-52 & Pre-
sumption,
Intuition
HTC
Hematocrit values depend on the number and size of red blood cells. Lower
HTC may be due to anemia, or WBC hematoproliferative disorders, while
increased HTC may due to increased erythrocytes number, or enlarged RBC
MCV (macrocytic anemia). Extremes from both sides may be unfavourable
for survival.
53-56 & Pre-
sumption,
Intuition
7
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MCV
The incidence of vitamin B12 and folate deficiency increases with age and
may lead to macrocytosis (indicated by increased MCV). Macrocytosis may
also develop as a result of age-related shortened RBCs life-span,
independently of vitamin B12 and folate deficiency. These large RBCs are
known to have difficulties in passing through capilary vessel network, leading
to insufficient tissue supply with oxygen and nutritients. Older people with
these disturbancies are more likely to have poorer cognitive functioning and
increased mortality. Some subpopulations of older people are especially prone
to macrocytosis, including those with chronic gastritis, chronic kidney and
heart disease, as well as those with multi-morbidity.
57-60 &
Presumption
FE
Testing serum iron is a part of complete blood count test. As according to the
evidence, both, lower and upper extremes of the interval values, recorded in
the sample, might be unbeneficial for survival.
61-62 & Pre-
sumption,
Intuition
ALB
Lower serum albumin, in older people, although still within the reference
range, may be a marker of low grade chronic inflammation, or more
specifically, of the frailty syndrome, characterized also with lower total
cholesterol, muscle wasing (energy-protein malnutrition)and anemia.
36, 63 &
Presumption
Clear
Decline in renal function, indicated by increased values of creatinine
clearance, is associated with a variety of pathophysiologic changes, including
hypertension, insulin resistance, other metabolic changes, increased
inflammation, the immune system dysfunction, protein malnutrition (muscle
vasting), endocrine disorders, anemia and blood rheology. Chronic renal
impairment has been recognized as the main risk factor for CVD and
dementia.
64-68 &
Presumption
HOMCIS
Increased serum concentrations of the amino-acid homocystein has been
found to have strong oxydative properties. Increased oxydative stress is a
driving force for the development of the main age-related chronic diseases. In
addition, hyperhomocysteinemia is an indicator of impaired DNA methylation
process and cell-cycling, which may have the greatest impact on the
functioning of cells with a high cell turn-over, such as immunocompetent
cells. Serum concentrations of homocystein > 12.5 µmol/L has been
confirmed as the risk factor for CVD and dementia. This disorder is closely
related to vitamin B12 and folic acid deficiency and frequently found in
subjects with chronic renal renal impairment, especially when it is associated
with increased level of inflammation and protein malnutrition.
69-71 &
Presumption
VITB12
Deficiency of B-vitamins, notably of vitamin B12 and folic acid, has been
confirmed as the main cause of mild hyperhomocysteinemia. The mechanism
which links these disorders into the same pathogenetic network is the
metabolic cycle of the amino acid methionine, an essential biochemical
reaction during DNA methylation reaction. This metabolic cycle is controlled
by the common set of enzymes. The activity of one of these enzymes, the
methylene tetrahydrofolate reductase. is also greatly influenced by the genetic
variations. Disorders associated with the impaired methylation reactions
include: DNA damage, genome instability, impaired cell proliferation and
insufficient neurotransmitter synthesis. These are all mechanisms during the
course of the development of the age-related diseases, including
atherosclerotic CVD, neurodegenerative disease nad cancer. The main causes
of vitamin B12 and folic acid deficiency, in older population, include low
dietary intake, impaired absorption due to chronic gastritis and oxidative
depletion due to chronic renal impairment.
72-74 &
Presumption
FOLNA The same as above
72-74 &
Presumption
8
Attribute Description References
INS
Increased serum insulin concentrations is a clinical marker of insulin
resistance - an insufficient action of insulin on insulin-sensitive target tissues,
notably muscles. Insulin resistance is a mechanism of impaired glucose
metabolism associated with obesity, diabetes, frailty and chronic renal
impairment. Increased serum insulin concentrations, >= 85.2 pmol/L, has
been accepted as the part of the insulin resistance (Metabolic) syndrome - a
cluster of clinical features including also abdominal obesity, hypertension,
increased Triglycerides and/or decreased HDL-cholesterol serum
concentrations. The prevalence of this syndrome increases in aging
population. It is a well accepted risk factor for the development of diabetes
and CVD. Recent studies also link folate deficiency, increased level of
inflammation and impaired blood rheology, to the Metabolic syndrome. They
also emphasize the possible gender differences in the Metabolic syndrome and
its role in the development of CVD.
75-78 &
Presumption
CORTIS
Serum cortisol secretion is a part of the stress-adaptive response of the
hypothalamo-pituitary-adrenal (HPA) axis. This is a dynamic feedback
network with circadian rhytmicity and pulsatile neurohormone secretion. The
HPA axis is the main neuroendocrine pathway which regulates the immune
system. Reversely, one of the most powerful stimuli of this axis is IL-6 - the
main cytokine of the inflammatory response. The complex pathogenetic
network, including obesity, dysregulation of the neuroendocrine stress axis,
increased inflammation and insulin resistance, has been found to be a risk
factor for CVD. It is not completely understood of how aging causes changes
in the HPA axis. It appears that there is no deficiency of adrenal production
of cortisol, but in its pulsatile and 24h rhytmic release. In older subjects,
serum cortisol secretion may vary more within a 24h period, as compared to
younger subjects. So, both lower and higher serum concentrations of cortisol
in the morning, might be detrimental for survival. In older population, there
is a close association between the HPA axis activation, depression / mood
disorders and neurodegenerative disorders (corresponding with cognitive
impairment and dementia). According to the recent meta-analysis, greater
diurnal decline of the HPA axis (drop between the morning and evening
cortisol), is associated with better physical performance in later life.
Epidemiologic studies have not confirmed the role of chronic activation of the
stress axis with increased mortality in later life.
79-83 & Pre-
sumption,
Intuition
PRL
The role of variations in serum prolactin concentrations, in aging diseases, has
not been clarified. Evidence indicate the association of increased serum
prolactin concentrations with the insulin resistance syndrome, chronic
inflammation, the immune system dysregulation,
depression/neurodegenerative diseases and chronic renal impairment.
84-86 &
Presumption
TSH
Isolated finding of mildly increased serum concentrations of the hormone TSH
is a marker of subclinical form of the primary hypothyreoidism - a frequent
disorder in older population. Evidence suggest the association of this disorder
with decreased bone mineral density in postmenopausal women, increased
cholesterol and increased risk for atrial fibrillation, while evidence are
controversial on the associations with CVD, cognitive impairment and
all-cause mortality. Evidence are in favour of no harmful effect of subclinical
hypothyreoidism on the overall mortality in elderly. According to the
evidence, hypothyreoidism and moderate subclinical hypothyreoidism (TSH
> 6 IU/ml) are associated with increased CV and all-cause mortality in
patients with multiple CV risk factors and clinically manifest vascular disease.
87-90 &
Presumption
9
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FT3
The thyroid gland hormones are rarely changed in the elderly. The most
frequent patterns of changes include decreased fT3 and normal or increased
fT4 - a sign of nonthyroidal illness (a peripheral tissue resistance on the
action of the thyroid gland hormones due to the existence of overt chronic
diseases). This pattern of the thyroid gland hormones changes is often
associated with chronic renal impairment and is unbeneficial for survival.
87-90 &
Presumption
FT4 The same as noted above
87-90 &
Presumption
RF
Rheumatoid factor positivity can be find for years before the onset of
rheumatoid arthritis and may be considered as the marker of increased CV
risk.
91
ANA
Increased serum concentrations of the auto-antibody ANA can be found in
healthy elderly people, but especially in association with different chronic
diseases. It may be a marker of the bias of the immune reaction towards the
prevalence of the antibody-mediated (humoral) immunity.
92 &
Presumption
IGE The same as noted under the allergic diseases
1,29-32 &
Presump-
tion,
Intuition
10
3 Terms extracted and the associated risk of mortality
Risk English description
no risk
. might be beneficial for survival
. protective against premature death
. may be protective
low risk
medium low risk
. increasing the risk for unfavorable outcomes
. may be non beneficial for survival
. may also have unfavorable effect
. well established measures of insulin resistance and CV risk
factor
. ... The strength of associations with the risk of mortality is not
well known
. may be unfavorable for survival
. might be detrimental for survival
. unfavorable pathogenetic background
. may affect survival
. might be unbeneficial for survival
. may be detrimental for healthy aging and longevity
. might be in an unfavorable position in respect to survival
. can be expected in conditions associated with insulin
resistance, diabetes, hypertension, etc.
medium risk
. may contribute to CV and overall mortality
. unfavorable for survival
. predictive power in CV and all-risk mortality
. unbeneficial for survival
. marker of increased CV risk
. strong impact on the development of many aging diseases
. may affect survival - severe cognitive impairment
. can be a marker of higher CV risk and death unfavorable
survival pattern
medium high risk
. has been confirmed as the risk factor for cvd and dementia
. strong mortality risk factor
. risk factor for frailty and premature death
. increased risk of CV and all-cause mortality
. increased cv and all cause mortality
. increased mortality risk
high risk
. it is a well accepted risk factor for the development of diabetes
and CVD
. main risk factor for cardiovascular disease - the main mortality
cause
. the higher grade ... the stronger association with death
. the highest mortality risk
. prognostic factor of all-cause and cardiovascular mortality
. main risk factor for cvd and dementia
. main cause of mild hyperhomocysteinemia
extremely high risk
. major cause of mortality
. major cause of mortality and also a CV risk factor
. strongest risk factor
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4 Laboratory normal values
Parameter Reference ranges
Glucose (fglu) 4.4 - 6.4 mmol/L
HBA1c 2.8 – 3.8 %
Total cholesterol 3.5 - 5.2 mmol/L
Triglycerides 0.5 - 1.8 mmol/L
HDL-cholesterol 0.9 - 1.4 mmol/L
IgG Antibodies on cytomegalovirus until 0.4 IU/ml
IgG antibodies Helicobacter pylori > 11 IU/ ml
IgA antibodies Helicobacter pylori > 11 IU/ ml
Total Leukocytes 3.4 - 10.0 × 109/L
(%) neutrophiles 44.0 - 72.0 %
(%) Monocytes 2 - 12 %
(%) Lymphocytes 20 - 46 %
C-reactive protein do 5.0 mg/L
Erythrocytes 4.34 - 5.72 × 1012/L
Haemoglobin 138 - 175 g/L
MCV 83.0 - 97.2 fL
Serum ferum 11.0 - 32.0 µmol/L
Serum albumine 35 - 52 g/L
Clearance 1.6 - 2.94 ml/s/1.73m2
Homocisteine 5,0 – 15,0 µmol/L
γ-globuline (GAMA) 7.6- 1 6.5 g/L
Vitamine B12 128 – 648 pmol/L
Folna (folic acid) 6 - 39 mM/L
Serum Cortisol (in the morning) 154 -638 nmol/L
Prolactin M 65.7 - 439.8, F 76.3 - 400.7 mIU/L
TSH 0,46 – 4,68 Ul/ml
fT3 4.26 - 8.10 pmol/L
fT4 10 - 28.2 pmol/L
Anti- nuclear Antibodies (ANA) until 23 µIU/ml
IgE antibodies <114 kIU/L
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5 Forecast arguments
This section provides an associated risk by attributes in isolation. It is important to give an importance
value to each of this rules so we know how important these are in comparison with the loops.
R1. Age
- < 60→ low risk
- [60, 65]→ medium low risk
- [66, 70]→ medium risk
- [71, 75]→ high risk
- [76, 80]→ extremely high risk
- > 80→ medium risk
R2. Hyper
- no→ low risk
- yes→ high risk
R3. DM
- yes→ high risk
- IGT → medium risk
R4. HbA1c
- < 2.8 or > 3.8 → medium low risk
R5. Chol
- > 5.18 and < 6.19→ medium risk
- >= 6.19→ high risk
Source: https://medlineplus.gov/
magazine/issues/summer12/articles/
summer12pg6-7.html
R6. HDL
- > 1.0→ no risk
- < 1.0→ medium-low risk
R7. Statins
- yes and chol > 5.18→ low risk
R8. Anticoag
- yes→ medium risk
R9. CVD
- yes→ extremely high risk
R10. BMI
- < 20 or >= 30 or [26, 29] → medium
risk
R11. w/h
- > 1 and male→ medium low risk
- > 0.8 and female→ medium low risk
R12. COPB
- yes→ extremely high risk
R13. Aller d
- yes→ no risk
Importance [0, 100]:
1. Dr allerg
- yes→ medium low risk
R14. Analg
- yes→ low risk
R15. Neo
- yes→ medium low risk
R16. Derm
- yes→ medium low risk
R17. OSP
- yes→ medium risk
R18. PSY
- yes→ medium risk
R19. MMS
- < 10→ high risk
- >= 10 and < 25→ medium low risk
R20. CMV
- > 8.1→ medium high risk
Source: https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC2877470/
R21. HPA
- > 11.1→ medium low risk
R22. LE
- men and > 6.8→ medium risk
- women and > 6.5→ medium risk
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Source: https://www.hindawi.com/
journals/jar/2014/475093/
R23. CRP
- > 3→ medium high risk
Source: http://eurheartj.oxfordjournals.
org/content/31/13/1624.long
R24. MO
- > 8.6→ medium risk
Source: Last quartile of the dataset and at-
tribute description.
R25. Ly
- > 40→ medium risk
- < 20→ medium high risk
R26. E
- men and < 4.52→ medium high risk
- woman and < 4.10 → medium high
risk
- men and > 5.9→ medium low risk
- womann and > 5.10 → medium low
risk
Source: http://emedicine.medscape.com/
article/2054474-overview
R27. Hb
- men and (< 140 or > 175) → medium
low risk
- women and (< 123 or > 153) →
medium low risk
Source: http://emedicine.medscape.com/
article/2085614-overview
R28. HTC
- > 0.44→ medium low risk
- men and < 0.42→ medium low risk
- women and < 0.38 → medium low
risk
Source: http://hyper.ahajournals.org/
content/60/3/631.long
R29. MCV
- > 96→ medium risk
Source: https://emedicine.medscape.
com/article/2085770-overview
R30. ALB
- < 35→ medium high risk
Source: Laboratory normal values
R31. Clear
- men and < 2.08→ high risk
- women and < 1.58→ high risk
R32. HOMCIS
- > 12.7→ medium high risk
R33. VITB12
- < 258→ medium low risk
Source: doi:10.1177/1741826711424568
R34. FOLNA
- < 11.4→ medium high risk
Source: doi:10.1177/1741826711424568
R35. INS
- > 12.26→ medium high risk
Source: https://doi.org/10.2337/
dc11-1657
R36. CORTIS
- < 193.3 or > 772.52 → medium low
risk
Source: http://emedicine.medscape.com/
article/2088826-overview
R37. PRL
- men and > 439.8→ medium risk
- women and > 400.7→ medium risk
Source: https://doi.org/10.1093/
eurheartj/ehs233
R38. TSH
14
- CV D yes and > 6 → medium high
risk
Source: https://doi.org/10.1093/
eurheartj/ehs233
R39. FT3
- < 4.26 → medium risk
Source: doi:10.1093/ndt/gfu024
R40. FT4
- < 14 and FT3 < 4.26 → medium risk
Source: doi:10.1093/ndt/gfu024
R41. RF
- > 60→ medium risk
Source: doi:10.1136/ard.2009.110536
R42. ANA
- > 32→ medium low risk
Source: last quartile of dataset and attribute
description.
R43. IGE
- > 114→ no risk
Source: doi:10.1007/s10552-014-0489-9
R44. FE
- < 10.9 or > 18→ medium low risk
Source: first and last quartile of dataset and
attribute description
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6 Preferences
Preferences over pairs of attributes.
1. Age > important than sex
2. Hyper > sex
3. Hyper > age
4. DM > hyper
5. DM > age
6. Chol = HDL
7. FGlu = HbA1c
8. Anticoag > statins
9. CVD > BMI
10. CVD > hypert
11. CVD > age
12. CVD > Neo
13. w/h > BMI
14. skinf > BMI
15. COPB > aller d
16. Dr aller > aller d
17. Analg = CRP
18. Analg > Derm
19. Neo > Derm
20. OSP > Neo
21. OSP > aller d
22. OSP > BMI
23. Psy > Derm
24. MMSE > Psy
25. CMV = EBV
26. HPA > LE
27. HPA = MCV
28. CRP > LE
29. MO > LE
30. LY > LE
31. HTC > HB
32. E=HB
33. VITB12 = MCV
34. VITB12 = FOLNA
35. Skinf > ALB
36. MMSE = VITB12
37. w/h > INS
38. HOMCIS > Clear
39. Clear > Derm
40. Clear > Aller d
41. Clear > BMI
42. HOMCIS = PRL
43. Clear > age
44. PRL > CORTIS
45. PRL=TSH
46. TSH > Chol
47. TSH = FT3
48. RF < CVD
49. CRP > ANA
50. ANA = GAMA
51. IGE = Aller d
6.1 Attacks based on preferences
1. R2 ⇒ R1
2. R3 ⇒ R2
3. R3 ⇒ R1
4. R8 ⇒ R7
5. R9 ⇒ R10
6. R9 ⇒ R2
7. R9 ⇒ R1
8. R9 ⇒ R16
9. R11 ⇒ R10
10. R12 ⇒ R13
11. R14 ⇒ R13
12. R15 ⇒ R17
13. R16 ⇒ R17
14. R18 ⇒ R16
15. R18 ⇒ R13
16. R18 ⇒ R10
17. R19 ⇒ R17
18. R20 ⇒ R19
19. R22 ⇒ R23
20. R24 ⇒ R23
21. R25 ⇒ R23
22. R26 ⇒ R23
23. R29 ⇒ R28
24. R11 ⇒ R36
25. R33 ⇒ R32
26. R32 ⇒ R17
27. R32 ⇒ R13
28. R32 ⇒ R10
29. R32 ⇒ R1
30. R38 ⇒ R37
31. R39 ⇒ R5
32. R9 ⇒ R42
33. R24 ⇒ R43
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7 Contradictions
These are contradictions between attributes that might invalidate the use of one attribute.
1. If Age > 60 then Aller d can not exist
2. If (Age < 60 and not DM and not Hyper) or (Age between 61 and 65) then Clear is not low
3. If Clear is low then HOMCIS is not low
4. If Clear is low then PRL is not low
5. If Clear is low then TSH is not low
6. If VITB12 is not low then MCV can not be increased
7. If COPB then Aller d can not exist
8. If INS is low then w/h can not be high
9. If no CVD then no Anticoag
10. If low Chol then no Statins
11. If OSP then CRP can not be low
12. If CVD then increased Skinf
13. If BMI is high than Skinf can not be increased
14. If CVD than Skinf can not be low
15. If MMSE >= 25 then TSH can not be increased
16. If HOMCIS is low than Clear can not be low
17. If Chol is high than HTC can not be low
18. If IGE low than HPA is not high
19. If Clear is low and high CRP then low ALB.
17
20. If VITB12 is high then MCV can not be increased
21. If high HPA then low VITB12
22. If INS is low then HDL is not low
23. If DM than BMI can not be high
24. If DM than BMI can be high
Impact loops: Not implemented. 23 and 24 contradict each other.
25. If DM then w/h can not be low
26. If COPB than Skinf can not be low
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